BIENAIME JEAN JACQUES 4

What Happened

• Bienaime Jean Jacques, a director of Keros Therapeutics, received two awards on 2026-06-03 totaling 14,575 shares: 7,142 restricted stock units (RSUs) and a 7,433-share derivative award. Both were reported at $0.00 per share (no cash paid) on Form 4.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (appears timely).
• Awards: 7,142 RSUs (footnote F1) and 7,433 derivative shares (footnote F2); aggregated = 14,575 shares; reported acquisition price $0.00.
• Vesting: RSUs vest on the earlier of June 3, 2027 or the issuer’s 2027 annual meeting, subject to continued service (F1). The derivative grant vests in equal quarterly installments over the 12 months following June 3, 2026 and will be fully vested by the 2027 annual meeting, subject to continued service (F2).
• Shares owned after the transaction: not specified in the provided filing details.
• Transaction code: A (award/grant). No 10b5-1, tax-withholding, or late-filing indicators provided.

Context

• These are compensation awards (an RSU and a derivative grant) rather than open-market purchases or sales. Such grants are common forms of board compensation and reflect equity-based pay, not a direct open-market vote of confidence. The derivative award (F2) vests over the next year; the RSU vests by mid-2027, contingent on continued service.